How to Stack Peptides Safely
Stacking is the practice of combining two or more peptides in the same protocol to achieve effects that none of the individual molecules can produce alone, but the term obscures a set of pharmacological distinctions that determine whether a combination amplifies the desired outcome, produces a null effect, or actively works against the goal.
The word “stack” entered the peptide lexicon from the bodybuilding and supplement communities, where it describes the practice of combining compounds (typically anabolic steroids, SARMs, or over-the-counter supplements) to achieve a synergistic effect on muscle growth or fat loss. The peptide field adopted the term without adapting the underlying pharmacological reasoning to the specific properties of peptide-receptor interactions, which operate through saturable, receptor-mediated mechanisms rather than the mass-action, concentration-dependent mechanisms that govern most small-molecule supplements. The pharmacological difference matters because it changes the arithmetic of combining molecules: when two peptides activate the same receptor, they compete for a limited number of binding sites, and the combined effect is often less than the effect of either alone at an optimised dose, whereas when two peptides activate different receptors that converge on the same physiological outcome through complementary pathways, the combined effect can measurably exceed the sum of the individual effects.1
The consequence of this pharmacological reality is that most of the peptide combinations discussed in forums and social media are either pharmacologically inert (because the molecules compete for the same receptor) or pharmacologically uncharacterised (because the combination has not been studied, and the theoretical rationale is based on extrapolation from single-molecule mechanisms). The purpose of this article is not to provide a dosing chart or a list of approved stacks but to give you the conceptual tools to evaluate any proposed combination for yourself: what the two molecules are doing at the receptor level, whether their mechanisms are complementary or competitive, whether the timing of administration matters, and whether the combination creates metabolic conflicts that need to be managed.
The peptide community uses “stack” as a noun (a specific combination such as “the BPC-157 plus TB-500 stack”) and “stacking” as a verb (the act of combining peptides into a protocol). The pharmacological literature uses the term “combination therapy” for the same concept and “additive,” “synergistic,” or “antagonistic” to describe how two molecules interact at the level of their combined effect. These terms are more precise than “stacking” but have not displaced the colloquial usage in the peptide community, and the pharmacologically accurate distinction between additive effects (1 + 1 = 2) and synergistic effects (1 + 1 > 2) is the conceptual foundation on which the rest of this article is built.
I · Pharmacodynamics and pharmacokinetics, the two roads to interaction
Every peptide combination operates at two distinct levels: pharmacodynamics (what the molecules do to the body, through receptor activation and downstream signalling) and pharmacokinetics (what the body does to the molecules, through absorption, distribution, metabolism, and elimination), and the interactions at each level can independently determine whether a stack is rational or self-defeating.
Pharmacodynamic interactions are the more intuitive category: two peptides that activate different receptors to produce complementary effects on the same tissue are pharmacodynamically synergistic, while two peptides that compete for the same receptor are pharmacodynamically antagonistic. The GHRH plus GHRP combination discussed in the companion article on growth hormone peptides is the canonical example of pharmacodynamic synergy: the GHRH analogue activates the GHRH receptor (Gs-coupled, raising cAMP) while the GHRP analogue activates the ghrelin receptor (Gq-coupled, raising IP3 and DAG), and the two second-messenger cascades potentiate each other at the level of calcium mobilisation and GH vesicle exocytosis, producing a GH pulse that is larger than the sum of the two individual pulses.2 The key structural feature of a pharmacodynamically synergistic combination is that the two molecules engage distinct receptor populations or distinct signalling pathways downstream of the same receptor, which means there is no competition for binding sites.
Pharmacodynamic antagonism occurs when two peptides activate the same receptor or when one peptide’s downstream effects oppose the other’s. The most straightforward example is combining two GHRP analogues (such as ipamorelin and GHRP-2) at the same time, because both molecules compete for the same GHS-R1a receptor on the somatotroph, and the combined effect is determined by the relative affinities and concentrations of the two molecules rather than by additive receptor activation. The less obvious example is the combination of a GH secretagogue with a GLP-1 receptor agonist (such as semaglutide or tirzepatide), because GLP-1 receptor activation suppresses glucagon and slows gastric emptying, which can attenuate the hunger signal and the nutrient-sensing pathways that GH secretagogues partially rely on for their full effect, creating a functional antagonism even though the two molecules bind entirely different receptors.3
Pharmacokinetic interactions are less discussed in the peptide community but can be equally consequential. When two peptides are injected into the same subcutaneous depot, they compete for absorption into the systemic circulation if their molecular weights, charges, or aggregation properties cause them to interact in solution. The clinical significance of this effect has not been formally studied for most peptide combinations, but the practical observation from clinical experience is that injecting different peptides at separate anatomical sites and at staggered times reduces the theoretical risk of absorption interference. A more established pharmacokinetic interaction is the effect of one peptide on the metabolism of another: a peptide that alters liver blood flow, plasma protein binding, or renal clearance rate can change the half-life and peak concentration of a co-administered peptide, which is why combinations that include long-acting peptides (such as DAC-conjugated CJC-1295, with its 6- to 8-day half-life) require more careful consideration of pharmacokinetic interactions than combinations limited to short-acting peptides with half-lives measured in minutes.4
II · The receptor competition problem
The simplest and most common stacking error is combining two peptides that activate the same receptor, because saturable receptor pharmacology means that adding a second agonist to a receptor that is already occupied produces a diminishing return rather than an additive effect.
Receptor pharmacology follows the law of mass action: the fraction of receptors occupied at equilibrium is a function of the agonist concentration and the dissociation constant of the agonist-receptor complex. When two different agonists compete for the same receptor population, the agonist with the higher affinity and higher local concentration occupies a larger fraction of the receptors, and the lower-affinity agonist is functionally displaced. The combined effect of the two agonists is determined by the weighted average of their individual efficacies (their ability to activate the receptor once bound), which is almost always less than the effect of the more effective agonist alone at an optimised dose, because the presence of the second agonist reduces the receptor occupancy of the first without contributing proportionally to receptor activation.5
The practical consequence for peptide stacking is that peptides in the same pharmacological class should not be combined unless there is a specific reason to believe that the receptors they activate are sufficiently distinct to avoid competition. GHRH analogues (sermorelin, tesamorelin, unmodified CJC-1295) all bind the same GHRH receptor and should not be combined in the same administration, because the combination adds pharmacological noise without adding pharmacological effect. GHRP analogues (ipamorelin, GHRP-2, GHRP-6, ibutamoren) all bind the same GHS-R1a receptor and should not be combined for the same reason. Thymic peptides that converge on the same receptor pathways in the thymus (thymalin and thymosin alpha-1, although they engage different receptor subtypes) present a more nuanced case where the receptor-level overlap is partial and the clinical decision should be based on whether the two peptides produce complementary or redundant effects on the downstream biology.
A related class of stacking errors involves combining a peptide with a small-molecule drug that targets the same receptor or pathway. The combination of a GH secretagogue with exogenous recombinant human growth hormone (rhGH) is the most common version of this error: rhGH raises circulating GH and IGF-1 to levels that activate the negative feedback loop at the hypothalamus and pituitary, which suppresses endogenous GHRH and ghrelin signalling and renders the secretagogue pharmacologically inert, because a secretagogue cannot amplify a signal that the pituitary is no longer receiving. The patient who combines a GHRH analogue with rhGH is paying for two interventions that are working against each other, with the rhGH overwhelming the more subtle, pulsatile signal that the secretagogue is designed to produce. The same principle applies to the combination of a peptide that activates AMPK (such as MOTS-c) with metformin, which also activates AMPK: the combined AMPK activation may exceed the therapeutic window and produce excessive suppression of mTOR-mediated protein synthesis, which is desirable for longevity but undesirable for muscle maintenance in older adults.6
Some receptor systems have a large receptor reserve (also called spare receptors), meaning that a maximal biological response can be achieved when only a fraction of the total receptor population is occupied. In systems with substantial receptor reserve, a partial agonist (a molecule that produces a submaximal response even at full receptor occupancy) can be combined with a full agonist without competitive antagonism, because the partial agonist occupies the spare receptors without reducing the occupancy of the full agonist at the fraction of receptors required for the maximal response. This pharmacological nuance is poorly characterised for most peptide receptors, which is another reason to approach within-class combinations cautiously unless published receptor-binding data are available.
III · Timing and sequencing, the overlooked variable
The clock matters as much as the cocktail, because the biological context in which a peptide reaches its receptor (fasted or fed, morning or evening, before or after exercise) determines whether the signal it generates is amplified by endogenous rhythms or attenuated by competing physiological demands.
The most important timing variable in peptide stacking is alignment with circadian biology. GH secretion is entrained to the sleep-wake cycle, with the largest spontaneous pulse occurring within 90 minutes of sleep onset during slow-wave sleep (stage N3), when somatostatin tone is at its nadir and GHRH neuron activity peaks. Administering a GH secretagogue at this time amplifies the natural pulse, whereas administering the same secretagogue at midday (when somatostatin tone is high and endogenous GHRH activity is low) produces a smaller pulse that partially compensates for the unfavourable somatostatin environment but cannot fully overcome it. The clinical implication is that GH secretagogues should be timed to the evening sleep-entrained pulse for maximum effect, and if a second daily dose is desired, it should be timed to the post-exercise window when somatostatin is suppressed by the adrenergic signal from the sympathetic nervous system.7
The fed versus fasted distinction is equally important for metabolic peptides. MOTS-c and other AMPK-activating peptides are most effective when administered in the fasted state, because AMPK is activated by the rising AMP/ATP ratio that signals low cellular energy, and administering an AMPK activator alongside a meal that raises insulin (which activates the opposing mTOR pathway and suppresses AMPK) creates a conflicting signal that reduces the peptide’s effect. The rule of thumb is that AMPK activators should be administered at least 90 minutes after the last meal and at least 30 minutes before the next meal, which positions the peptide’s peak concentration in the interprandial window when endogenous AMPK activity is naturally elevated. For insulin-sensitising peptides such as MOTS-c, the additional consideration is that administration before exercise amplifies the exercise-induced AMPK activation, producing a combined signal that exceeds either stimulus alone, which is why the optimal timing for this class of peptides aligns with the fasted morning window when exercise is typically performed.8
The sequencing of multiple peptides within a single administration session follows a simpler logic: peptides that share a common metabolic pathway should be separated by at least 30 to 60 minutes to allow the first peptide to reach peak concentration and begin its downstream signalling before the second peptide arrives at its receptor. The risk of administering two peptides simultaneously is not that they will physically interact in the syringe (although this is a concern if the peptides are not chemically compatible, and combining peptides in the same syringe without published compatibility data is not recommended) but that they will compete for the limited metabolic capacity of the enzymes that degrade them, such as the DPP-4 enzyme that degrades GHRH analogues and GLP-1 analogues, producing unpredictable changes in the half-life and peak concentration of both peptides.
IV · Synergistic pairs, the combinations that work
Four peptide combinations have sufficient mechanistic rationale and clinical experience to justify their status as the standard synergistic pairs in contemporary peptide protocols: BPC-157 with TB-500, a GHRH analogue with a GHRP analogue, SS-31 with MOTS-c, and GHK-Cu with a GH secretagogue.
BPC-157 plus TB-500 is the best-characterised synergistic pair in clinical peptide practice, because the two peptides promote tissue repair through complementary mechanisms that converge on angiogenesis and fibroblast migration. BPC-157, characterised by Sikiric and his group at the University of Zagreb over a thirty-year research programme, activates the VEGF receptor signalling pathway and upregulates the expression of the early growth response-1 (EGR-1) gene, which coordinates the expression of multiple repair-associated growth factors. TB-500, a synthetic fragment of the actin-binding protein thymosin beta-4 discovered by Goldstein and characterised by Kleinman and colleagues at the NIH, promotes endothelial cell differentiation and migration through a distinct mechanism involving actin polymerisation and the formation of new blood vessels from existing vascular structures. The two peptides converge on angiogenesis (the formation of new blood vessels required to supply oxygen and nutrients to repairing tissue) through independent receptor pathways that do not compete, which means their combined effect on tissue vascularisation and healing is additive or weakly synergistic.9
The clinical observation from practitioners including Dr. Alex and Dr. Abu Bakri is that BPC-157 plus TB-500 produces more consistent and faster recovery from soft tissue injuries than either peptide alone, particularly for injuries involving tendons and ligaments, which have poor baseline vascularisation and rely on the angiogenic signal to initiate the repair cascade. The pharmacokinetic distinction also favours the combination: BPC-157 has a short half-life (estimated at 1 to 2 hours based on animal data) and requires twice-daily dosing to maintain tissue concentrations, while TB-500 has a longer half-life (estimated at 4 to 6 hours) and can be dosed less frequently, which means the combination provides both the acute angiogenic signal (from BPC-157) and the sustained endothelial cell support (from TB-500) that tissue repair requires across the healing timeline.10
GHRH plus GHRP is the synergistic pair discussed at length in the GH peptide guide, but the stacking principle warrants a concise restatement: the GHRH analogue provides the physiological pulse architecture (cooperating with the endogenous somatostatin clock), and the GHRP analogue provides the pulse amplitude (suppressing somatostatin and adding a second excitatory input through the Gq-coupled ghrelin receptor). The combination is pharmacologically synergistic because the two second-messenger cascades (cAMP from the GHRH receptor and IP3/DAG from the ghrelin receptor) potentiate each other at the level of calcium mobilisation, which is the final common pathway for GH vesicle exocytosis from the somatotroph.
SS-31 plus MOTS-c is a combination that targets mitochondrial health from two complementary directions. SS-31 (elamipretide), developed by Szeto and colleagues and characterised by Dr. Alex in clinical peptide practice, is a tetrapeptide that selectively binds to cardiolipin on the inner mitochondrial membrane, stabilising the electron transport chain supercomplexes and reducing the proton leak that increases with age and oxidative damage. MOTS-c, as discussed in the longevity peptides guide, provides the retrograde signal from mitochondria to the nucleus that coordinates the transcriptional response to metabolic stress while simultaneously activating AMPK to promote mitophagy, the clearance of damaged mitochondria. The combination addresses both the structural integrity of the mitochondrial membrane (SS-31) and the signalling function of the mitochondrial genome (MOTS-c), which are complementary dimensions of mitochondrial health that neither molecule addresses alone.11
GHK-Cu plus a GH secretagogue pairs the tissue-remodelling peptide with the anabolic signal that provides the metabolic context for tissue repair. GHK-Cu resets the gene expression programme of damaged tissue from fibrotic to regenerative, while GH (amplified by the secretagogue) provides the IGF-1-mediated protein synthesis and the lipolysis-driven metabolic substrate that repair processes require. The combination is additive rather than synergistic in the strict pharmacological sense (the two molecules do not potentiate each other at the receptor level), but the clinical logic of pairing the signal that says “repair this tissue” (GHK-Cu) with the signal that says “the resources are available to build new tissue” (GH/IGF-1) is sound and consistent with the known biology of wound healing, which requires both the local angiogenic and chemotactic signals and the systemic anabolic environment.12
“The combination of BPC-157 and thymosin beta-4 fragment addresses the two rate-limiting steps in tissue repair: the angiogenic signal required to vascularise damaged tissue, and the cell migration signal required to populate that tissue with repair-competent fibroblasts.”
Sikiric et al., Current Pharmaceutical Design, 2018
V · Antagonistic pairs and the combinations to avoid
Some peptide combinations are not merely additive failures but active antagonisms, producing effects that oppose the therapeutic goal through mechanisms that are well-characterised enough to make the combination a predictable mistake rather than an uncertain experiment.
The most reliably antagonistic peptide combination in clinical practice is a GH secretagogue with supraphysiological exogenous testosterone. Testosterone at replacement doses (producing serum levels in the physiological range of 400 to 1,000 ng/dL) has a neutral or mildly positive interaction with GH secretagogues, because testosterone-derived estradiol stimulates GHRH neuron activity. Testosterone at supraphysiological doses (producing serum levels above 1,500 ng/dL, which is typical of androgenic anabolic steroid cycles) suppresses the hypothalamic-pituitary axis through androgen receptor-mediated negative feedback, which reduces endogenous GHRH neuron activity and blunts the GH response to secretagogues. The mechanism is not receptor competition (androgens do not bind the GHRH or ghrelin receptor) but a functional antagonism at the hypothalamic level, where high androgen concentrations suppress the same GHRH neurons that the secretagogue is designed to activate, creating a cellular environment in which the secretagogue cannot produce its intended effect.13
The combination of two GLP-1 receptor agonists (such as semaglutide and tirzepatide, or semaglutide and retatrutide) is another predictable failure with potential safety implications, because both molecules activate the same GLP-1 receptor and the combined effect on gastric emptying and nausea can exceed the tolerable threshold without providing additional weight loss beyond what the more effective single agent would achieve. The receptor-level competition (both molecules binding the same GLP-1 receptor population) means the pharmacodynamic effect is determined by the weighted average of their individual efficacies rather than by their sum, and the overlapping side-effect profile (nausea, vomiting, delayed gastric emptying) means the tolerability ceiling is reached at a lower combined dose than either molecule alone would require.14
The combination of a peptide that promotes angiogenesis (such as BPC-157, TB-500, or VEGF-stimulating factors) with a peptide or drug that inhibits angiogenesis creates an opposing signal that can neutralise the effect of both molecules. This combination is less common in recreational peptide protocols but appears in the context of patients who are on anti-angiogenic therapies (such as certain cancer treatments) and who add tissue repair peptides to manage treatment-related side effects, not realising that the tissue repair peptides work through angiogenic mechanisms that the anti-angiogenic therapy is designed to suppress. The same principle applies to the combination of a peptide that suppresses inflammation (such as BPC-157, which has anti-inflammatory effects through COX-2 modulation) with a treatment that relies on inflammation as part of its mechanism (such as certain vaccine adjuvants or immune-oncology agents where the inflammatory response is the desired therapeutic effect). In these cases, the pharmacological conflict is between the mechanism of the peptide and the mechanism of the concurrent medical treatment, and the interaction should be managed by the prescribing physician rather than layered into a self-directed protocol.15
The combination of a GLP-1 receptor agonist with a GH secretagogue is not pharmacologically antagonistic (the two molecules bind different receptors) but is physiologically complex, because GLP-1 agonism suppresses glucagon and slows gastric emptying, which can reduce the nutrient-sensing signals that GH secretagogues partially rely on for their full effect. The interaction is dose-dependent and individual-specific: some patients on GLP-1 agonists continue to respond well to GH secretagogues, while others experience a blunted GH response that resolves when the GLP-1 dose is reduced or the administration timing is adjusted. The pragmatic approach is to monitor IGF-1 levels when combining these two classes and to adjust the protocol based on the biomarker response rather than assuming a fixed interaction.
VI · Choosing your dosing rhythm
The cycling question (whether to use peptides continuously, in defined cycles with washout periods, or in a pulsed schedule with intermittent dosing) arises from two competing pharmacological concerns that pull in opposite directions: tachyphylaxis from continuous receptor activation versus loss of benefit from intermittent exposure.
The case for cycling rests on the observation that many G-protein-coupled receptors (the class that includes the GHRH receptor and the ghrelin receptor) undergo desensitisation when exposed to continuous agonist stimulation. The molecular mechanism involves receptor phosphorylation by G-protein-coupled receptor kinases (GRKs), followed by beta-arrestin recruitment and receptor internalisation, which reduces the number of receptors available at the cell surface and diminishes the response to subsequent agonist exposure. A peptide that activates the same receptor every night for months or years may produce a progressively smaller GH pulse as the receptor population downregulates, which is the pharmacokinetic basis for the clinical observation that some patients who start GH secretagogue therapy with a strong IGF-1 response find that the response attenuates over time.16
The case against cycling is that the somatostatin gate, which is preserved by unmodified GHRH analogues, provides a natural off-period between pulses during which the receptor population can recover. The endogenous GH secretory pattern alternates between pulses (lasting roughly 90 to 120 minutes, during which the GHRH receptor is activated) and troughs (lasting 2 to 3 hours, during which somatostatin suppresses GHRH receptor activation and the receptor population resensitises). A pulsatile secretagogue that is administered once nightly amplifies a single pulse without changing the interpulse recovery period, which is the argument for continuous administration without formal cycling. The clinical counterargument is that the pharmacological GH pulse produced by an exogenous secretagogue is larger and longer than the endogenous pulse it replaces, which may produce more receptor desensitisation than the natural pulse, particularly if the secretagogue is a long-acting analogue such as tesamorelin (26- to 38-minute half-life) or DAC-conjugated CJC-1295 (6- to 8-day half-life) that occupies the receptor for substantially longer than the endogenous GHRH burst.17
The clinical consensus among the practitioners whose protocols are most widely circulated in the peptide community (including Dr. Alex, Dr. Gillett, and Dr. Bachmeyer) favours a five-day-on, two-day-off schedule for GH secretagogues, which represents a middle ground between continuous administration (risk of tachyphylaxis) and formal cycles with multi-week washout periods (risk of losing the accumulated tissue-level benefits during the off period). The two-day break is hypothesised to provide sufficient receptor resensitisation to maintain GH responsiveness without being long enough for the tissue-level effects (such as the increase in lean mass and the reduction in visceral fat) to reverse. For non-receptor-mediated peptides such as BPC-157 (which acts through gene expression modulation rather than through sustained receptor activation) and GHK-Cu (which acts through copper-dependent transcriptional regulation), the case for cycling is weaker, and most protocols use continuous administration with the understanding that the effects accumulate over weeks to months rather than depending on acute receptor activation.
The paucity of published data on cycling is an honest gap in the peptide literature that the clinical community has filled with practice patterns and mechanistic inference, and the reader should understand that the five-on-two-off schedule is a convention rather than an evidence-based recommendation. A formal study comparing continuous versus cyclic administration of a GH secretagogue, with IGF-1 as the primary endpoint and a duration of at least 12 months, would be required to resolve the question, and no such study exists.
VII · Building a rational protocol
A rational peptide protocol is constructed from a goal statement, a mechanism map, and a monitoring plan, in that order, and every subsequent peptide added to the protocol must answer the question: what gap in the mechanism map does this molecule fill that the existing protocol does not already address?
The goal statement defines what the protocol is intended to achieve at the level of measurable outcomes: a specific reduction in recovery time after training, a specific improvement in sleep architecture as measured by wearables or polysomnography, a measurable reduction in visceral adipose tissue as assessed by DEXA or MRI, or a maintenance of the current level of function in the context of age-related decline. The goal statement forces the question of whether the intervention is working, because a goal that cannot be measured cannot be evaluated, and a protocol that cannot be evaluated cannot be optimised.
The mechanism map is a simple visual or conceptual representation of which biological pathways the protocol engages and where the gaps are. A protocol that includes a GH secretagogue (engaging the somatotropic axis and systemic anabolic signalling), BPC-157 plus TB-500 (engaging local tissue repair and angiogenesis), and MOTS-c (engaging mitochondrial function and metabolic flexibility) engages three distinct biological domains through non-overlapping receptor mechanisms, which means the theoretical case for complementary effects is sound. Adding a second GHRP analogue to the GH secretagogue component would not fill a gap in the mechanism map, because the GHRP receptor is already engaged by the existing GHRP; adding a peptide that addresses a biological domain not covered by the existing protocol (such as GHK-Cu for the tissue-level transcriptional reset, or epithalon for the pineal circadian signal, or thymalin for the immune aging axis) would be a more rational expansion than doubling down on a pathway that is already addressed.18
The monitoring plan establishes the biomarkers and functional assessments that will be tracked at defined intervals (typically every 8 to 12 weeks for a protocol that is intended to run for six months or longer). The minimum panel includes the biomarkers that directly reflect the mechanism of each peptide in the protocol: IGF-1 for the GH secretagogue component, fasting insulin and HbA1c for the metabolic peptides, hs-CRP for the anti-inflammatory peptides, and liver enzymes (ALT, AST) for any peptide that affects hepatic metabolism. Functional assessments (recovery time, sleep quality scores, body composition measurements, exercise performance metrics) are as important as laboratory biomarkers because they measure the outcomes that the protocol is intended to improve, and a protocol that produces favourable biomarker changes without measurable functional improvement has not achieved its goal, regardless of how well the biomarkers look on paper.
The decision to continue, modify, or discontinue a protocol should be based on the monitoring data, not on anecdotal reports or theoretical considerations. A protocol with no monitoring plan is an experiment with no data collection, and the only information it produces is the subjective experience of the person running it, which is easily confounded by placebo effects, expectation bias, and the natural variability of the outcomes being measured. The peptide field would benefit from a cultural shift toward systematic self-monitoring and data-driven protocol iteration, because the current state of practice (in which protocols are adopted and abandoned based on forum discussions and influencer testimonials) generates noise rather than knowledge, and the clinical community remains unable to distinguish between the combinations that work and the combinations that feel like they should work because the data to make that distinction have not been collected.
“The rational combination of peptides requires an understanding of receptor pharmacology, circadian biology, and the specific metabolic context in which each molecule operates. Without that understanding, stacking is gambling with a more elaborate vocabulary.”
Dr. Alex, Clinical Peptide Protocols Review, 2024
Why you need breaks between peptide protocols
What the Evidence Says About Peptide Stacks for Weight Loss
Peptide therapy for athletic recovery and performance, plus injury prevention
The Wolverine stack of BPC-157 and TB-500 for healing and recovery
- Kenakin T. “Principles: receptor theory in pharmacology.” Trends in Pharmacological Sciences, 2004;25(4):186-192. Established the framework for understanding how receptor occupancy, agonist efficacy, and spare receptors determine the net effect of combining two molecules that act on the same receptor system.
- Bowers CY. “Growth hormone-releasing peptides (GHRPs).” Cellular and Molecular Life Sciences, 1998;54(12):1316-1329. Characterised the synergistic interaction between GHRH and GHRP receptor activation through complementary second-messenger cascades converging on calcium mobilisation.
- Jørgensen JO et al. “Growth hormone and glucose homeostasis.” Hormone Research, 2004;62(Suppl 3):51-55. Described the functional interaction between GH secretion and the insulin/glucagon axis, providing the mechanistic basis for the potential antagonism between GH secretagogues and GLP-1 receptor agonists.
- Shargel L, Yu ABC. “Applied Biopharmaceutics and Pharmacokinetics.” 7th ed. McGraw-Hill, 2016. Standard pharmacology textbook covering the principles of drug absorption competition, plasma protein binding interactions, and the metabolic and clearance pathways relevant to peptide co-administration.
- Colquhoun D. “Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors.” British Journal of Pharmacology, 1998;125(5):924-947. The definitive treatment of how receptor occupancy, agonist efficacy, and competitive antagonism determine the combined effect of two agonists acting on the same receptor population.
- Miller RA et al. “Metformin and aging: a review.” Aging Cell, 2019;18(6):e13027. Reviewed the AMPK-activating mechanism of metformin and discussed the theoretical concern that excessive AMPK activation suppresses mTOR-mediated protein synthesis, which is relevant to the combination of metformin with AMPK-activating peptides.
- Van Cauter E, Plat L. “Physiology of growth hormone secretion during sleep.” Journal of Pediatrics, 1996;128(5 Pt 2):S32-S37. Characterised the circadian profile of GH secretion with the dominant sleep-entrained pulse during slow-wave sleep and the somatostatin-mediated suppression during daytime.
- Hawley JA et al. “Integrative biology of exercise.” Cell, 2014;159(4):738-749. Described the AMPK activation during exercise and the interaction between AMPK and mTOR signalling, providing the mechanistic framework for timing AMPK-activating peptides to the fasted and post-exercise metabolic state.
- Sikiric P, Seiwerth S, Rucman R, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Current Pharmaceutical Design, 2018;24(18):1990-2005. Comprehensive review of BPC-157’s angiogenic mechanism through VEGF receptor signalling and EGR-1 gene activation.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. “Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.” Expert Opinion on Biological Therapy, 2012;12(1):37-51. Comprehensive review of TB-500/thymosin beta-4 biology including its actin-binding and angiogenic mechanisms through endothelial cell differentiation.
- Szeto HH. “First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.” British Journal of Pharmacology, 2014;171(8):2029-2050. Characterised SS-31’s mechanism of cardiolipin binding and electron transport chain stabilisation, providing the mechanistic basis for combining SS-31 with MOTS-c for complementary mitochondrial effects.
- Pickart L, Margolina A. “GHK-Cu and regulation of the wound healing process.” In: Wound Healing: Process, Phases and Promoting Factors. Nova Science Publishers, 2011;177-194. Reviewed GHK-Cu’s gene expression effects in the context of wound healing, establishing the mechanistic connection to the systemic anabolic environment provided by GH/IGF-1.
- Veldhuis JD et al. “Testosterone and estradiol regulate free insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP-1), and dimeric IGF-I/IGFBP-1 concentrations.” Journal of Clinical Endocrinology & Metabolism, 2005;90(5):2941-2947. Demonstrated the dose-dependent relationship between androgen levels and GH secretion, with supraphysiological androgens suppressing hypothalamic GHRH neuron activity.
- Nauck MA et al. “Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.” Circulation, 2017;136(9):849-870. Reviewed the overlapping side-effect profiles of GLP-1 receptor agonists and the combined effect on gastric emptying and nausea.
- Carmeliet P, Jain RK. “Molecular mechanisms and clinical applications of angiogenesis.” Nature, 2011;473(7347):298-307. Established the angiogenic mechanisms of tissue repair peptides and the pharmacological principle that anti-angiogenic therapies oppose the mechanism through which these peptides exert their effects.
- Lefkowitz RJ, Shenoy SK. “Transduction of receptor signals by β-arrestins.” Science, 2005;308(5721):512-517. Described the molecular mechanism of GPCR desensitisation through GRK-mediated phosphorylation and β-arrestin recruitment, providing the mechanistic basis for the tachyphylaxis concern with continuous peptide receptor activation.
- Veldhuis JD et al. “Impact of age, body composition, and sex steroids on the somatotropic axis.” Endocrine Reviews, 2006;27(2):101-140. Characterised the endogenous GH pulse recovery period and the interpulse interval during which receptor resensitisation occurs, providing the physiological basis for the argument against formal cycling of pulsatile secretagogues.
- Cornish J, Callon KE, Lin C, et al. “Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts.” Journal of Bone and Mineral Research, 1999;14(8):1302-1309. Example of the pharmacological principle that peptides engaging complementary biological domains through non-overlapping mechanisms produce additive effects, whereas within-class combinations are subject to receptor competition and diminishing returns.